Heart Test Laboratories Inc

Heart Test Laboratories, Inc. is a medical technology company focused on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG’s clinical usefulness. Its objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It offers MyoVista, a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. The company was founded in 2008 and is headquartered in Southlake, TX.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HeartSciences, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. Its objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It offers MyoVista, a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. The company was founded in 2008 and is headquartered in Southlake, TX.

Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd (“Cardiact”) to be used in its heart screening program of members of the Association of Garda Sergeants and Inspectors (“AGSI”).  In addition to the purchase of a MyoVista® device, Cardiact has placed an initial supplies order covering 2,400 patient tests.

HeartSciences' MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

Heart Test Laboratories (NASDAQ: HSCS ) stock is taking off on Wednesday despite a lack of news concerning the medical technology company. Investors will note that Heart Test Laboratories hasn't put out any new press releases or filings with the Securities and Exchange Commission (SEC) that explain today's rally.

Why Is Heart Test Laboratories (HSCS) Stock Up 298% Today?

Arcutis Biotherapeutics

Mountain Crest Acquisition Corp II

Evelo Biosciences Inc

SINTX Technologies Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)

Heart Test Laboratories (NASDAQ: HSCS ) stock is on the move Thursday after announcing an agreement with the Icahn School of Medicine at Mount Sinai. This new agreement has Heart Test Laboratories' HeartSciences working with Icahn Mount Sinai to commercialize electrocardiographic artificial intelligence ( AI ) algorithms and assets.

Why Is Heart Test Laboratories (HSCS) Stock Moving Today?

Southlake, TX, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today provided a business update and reported financial results for the first quarter fiscal 2024 ended July 31, 2023.

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

Southlake, TX, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 11:30 am ET.

HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase

Southlake, TX, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been named Electrocardiography Advancement Specialists of the Year 2023 – USA, in the Global Health & Pharma (GHP) Global Excellence Awards.

HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards

Southlake, TX, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has extended its distribution channel through a new distribution agreement with MedPhy Technologies Pvt. Ltd. located in Mumbai, India.

HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India

Southlake, TX, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has signed a distribution agreement with FJ Medical, Denmark.

HeartSciences Signs Distribution Agreement with FJ Medical, Denmark

Southlake, TX, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces that its MyoVista® wavECGTM has been selected by PanaceaFlo Ltd to be used in Dublin, Ireland in its heart screening evaluation study.

HeartSciences' MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation

European Patent Allowed for Quantification by an ECG of Key Heart Measures using AI European Patent Allowed for Quantification by an ECG of Key Heart Measures using AI

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

Southlake, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces that its MyoVista® wavECGTM has been selected for commercial use in clinical practice by the Naya Imaging Center in Hvidore, Denmark.

MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark

Southlake, Texas, July 19, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today provided a business update and reported financial results for the fiscal year ended April 30, 2023.

HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results

Southlake, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces it has been recognized by Healthcare Tech Outlook Magazine as a 2023 Top healthcare artificial intelligence solutions provider , highlighting the Company's MyoVista device.

HeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine

Southlake, Texas, May 09, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through the early detection of heart disease, today announces completion of patient enrollment for its MyoVista wavECG pivotal study for FDA De Novo submission.

HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG

Southlake, Texas, May 08, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through the early  detection of heart disease, today announces that CEO, Andrew Simpson, will participate at the Inaugural EF Hutton Global Conference being held May 10 – 11, 2023, at the Plaza Hotel in New York City.

HeartSciences to Participate at the Inaugural EF Hutton Global Conference

Southlake, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a next-generation, AI ECG medical technology company focused on transformation of an ECG (also known as an EKG) into a far more valuable screening tool to help address the significant diagnostic gap in heart disease and save lives, today announces that CEO, Andrew Simpson, will participate in The Benchmark Company's Virtual Individual Investor Healthcare Conference.

HeartSciences to Participate in The Benchmark Company's Virtual Individual Investor Healthcare Conference

Southlake, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today announces that CEO Andrew Simpson will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023.

HeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023

Southlake, Texas, March 16, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today provided a business update and reported financial results for the fiscal 2023 third quarter ended January 31, 2023.

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2023 Financial Results

Southlake, Texas, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI), today announced that Andrew Simpson, Chief Executive Officer of HeartSciences, has been invited to appear as a featured guest on the Big Biz Show , an Emmy Award-winning nationally syndicated radio and TV program.

HeartSciences CEO Invited as Featured Guest on The Big Biz Show, February 7 at 11:45 a.m. Pacific Time

HeartSciences (NASDAQ: HSCS ) stock is on the move Monday as investors react to a new patent granted by the Israel Patent Office. That patent covers the use of AI alongside the company's ECG devices.

HSCS Stock Alert: HeartSciences Receives Israeli Patent for AI Heart-Disease Detector

Israeli patent covers a country known as a hotbed for medical device innovation Israeli patent covers a country known as a hotbed for medical device innovation

HeartSciences Granted Key Israeli International Patent for its MyoVista® Wavelet Technology Utilizing Artificial Intelligence (AI) for Early Detection of Heart Disease

Southlake, Texas, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI), today announced it has been granted Korean Patent No. 10-2490960 from the Korean Intellectual Property Office (KIPO).

HeartSciences Announces Further Internationalization of its Patent Portfolio

Aethlon Medical

G Medical Innovations Holdings Ltd

Can these technical indicators help you make money with penny stocks? The post 3 Tips for Using Technical Indicators to Find Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Tips for Using Technical Indicators to Find Penny Stocks to Buy

Heart Test (NASDAQ: HSCS ) stock is taking off on Monday as investors react to a new rating and price target for the medical device company. Ascendiant Capital is behind this as the firm's analysts initiate coverage of HSCS stock with a “buy” rating.

News for Heart Test Laboratories Inc Stock (HSCS)